BACKGROUND: Early experiments using ligand-binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis. METHODS: To verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERbeta. RESULTS: All 40 cases of extraabdominal fibromatosis were at least focally positive for ERbeta. Thirty-three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11-50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERalpha. CONCLUSIONS: Although extraabdominal fibromatosis does not express ERalpha, there appears to be nearly uniform expression of ERbeta. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses. Copyright 2005 American Cancer Society.
BACKGROUND: Early experiments using ligand-binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis. METHODS: To verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERbeta. RESULTS: All 40 cases of extraabdominal fibromatosis were at least focally positive for ERbeta. Thirty-three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11-50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERalpha. CONCLUSIONS: Although extraabdominal fibromatosis does not express ERalpha, there appears to be nearly uniform expression of ERbeta. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses. Copyright 2005 American Cancer Society.
Authors: Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates Journal: Cancer Sci Date: 2012-11-15 Impact factor: 6.716
Authors: Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki Journal: Clin Cancer Res Date: 2011-03-29 Impact factor: 12.531
Authors: Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney Journal: Pediatr Blood Cancer Date: 2012-12-31 Impact factor: 3.167